- Home
- SVII vs INBX Comparison
SVII vs INBX Comparison
Compare SVII & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- INBX
- Stock Information
- Founded
- SVII 2021
- INBX 2010
- Country
- SVII United States
- INBX United States
- Employees
- SVII N/A
- INBX N/A
- Industry
- SVII Blank Checks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- INBX Health Care
- Exchange
- SVII Nasdaq
- INBX Nasdaq
- Market Cap
- SVII 119.4M
- INBX 430.2M
- IPO Year
- SVII 2022
- INBX 2020
- Fundamental
- Price
- SVII $14.20
- INBX $35.94
- Analyst Decision
- SVII
- INBX Hold
- Analyst Count
- SVII 0
- INBX 2
- Target Price
- SVII N/A
- INBX N/A
- AVG Volume (30 Days)
- SVII 146.5K
- INBX 162.4K
- Earning Date
- SVII 01-01-0001
- INBX 11-13-2025
- Dividend Yield
- SVII N/A
- INBX N/A
- EPS Growth
- SVII N/A
- INBX N/A
- EPS
- SVII 0.17
- INBX N/A
- Revenue
- SVII N/A
- INBX $1,400,000.00
- Revenue This Year
- SVII N/A
- INBX $563.00
- Revenue Next Year
- SVII N/A
- INBX $230.77
- P/E Ratio
- SVII $85.06
- INBX N/A
- Revenue Growth
- SVII N/A
- INBX N/A
- 52 Week Low
- SVII $11.20
- INBX $10.81
- 52 Week High
- SVII $14.80
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- SVII 76.15
- INBX 66.29
- Support Level
- SVII $12.18
- INBX $31.28
- Resistance Level
- SVII $14.80
- INBX $35.96
- Average True Range (ATR)
- SVII 0.53
- INBX 2.17
- MACD
- SVII 0.16
- INBX -0.16
- Stochastic Oscillator
- SVII 78.81
- INBX 66.47
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.